Para alem de serem um dos melhores sectores este ano ainda têm espaço para registar subidas fortes nestes dias.
Genentech (DNA: up $7.48 to $70.09, Research, Estimates) jumped more than 11 percent in early trading after the company presented findings at a weekend meeting of the American Society of Clinical Oncology that showed its experimental colon cancer treatment helped patients live 50 percent longer than standard chemotherapy.
In addition, ImClone (IMCLE: up $8.60 to $37.10, Research, Estimates) presented findings from a study by its European partner that showed its cancer treatment Erbitux was as effective as the company originally claimed. It's shares also rose nearly 30 percent at the open.
O Clubeinvest.com informa que nenhuma da informação
aqui facultada deverá ser entendida como conselho ou recomendação
de qualquer tipo de transacção ou investimento.
